Autoreactive CD4+ T-cell clones to β2-glycoprotein I in patients with antiphospholipid syndrome: Preferential recognition of the major phospholipid-binding site

Blood

Volumn 98, Issue 6, 2001, Pages 1889-1896

  Arai, Takahide ^a,b,c   Yoshida, Kazue ^a,b,c   Kaburaki, Junichi ^a,b,c   Inoko, Hidetoshi ^a,b,c   Ikeda, Yasuo ^a,b,c   Kawakami, Yutaka ^a,b,c   Kuwana, Masataka ^a,b,c  

^a KEIO UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^b TOKYO ELECTRIC POWER COMPANY   (Japan)

^c TOKAI UNIVERSITY SCHOOL OF MEDICINE   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

BETA2 GLYCOPROTEIN 1; CD4 ANTIGEN; CD40 ANTIGEN; EPITOPE; INTERLEUKIN 6; LIGAND; MONOCLONAL ANTIBODY; PHOSPHOLIPID;

ADULT; ALLELE; AMINO ACID SEQUENCE; ANTIGEN DETECTION; ANTIGEN EXPRESSION; ANTIGEN RECOGNITION; ANTIPHOSPHOLIPID SYNDROME; ARTICLE; B LYMPHOCYTE ACTIVATION; BINDING SITE; CASE REPORT; CONTROLLED STUDY; CYTOKINE PRODUCTION; CYTOKINE RELEASE; FEMALE; HELPER CELL; HUMAN; HUMAN CELL; LYMPHOCYTE CLONE; MALE; PRIORITY JOURNAL; T LYMPHOCYTE ACTIVATION;

EID: 0035885939     PISSN: 00064971     EISSN: None     Source Type: Journal    
DOI: 10.1182/blood.V98.6.1889     Document Type: Article

References (54)

1. Harris EN, Chan JK, Asherson RA, Aber VR, Gharavi AE, Hughes GRV. Thrombosis, recurrent fetal loss, and thrombocytopenia: predictive value of the anticardiolipin antibody test. Arch Intern Med. 1986;146:2153-2156.
2. McNeil HP, Simpsod RJ, Chesterman CN, Krilis SA. Antiphospholipid antibodies are directed against a complex antigen that includes a lipid-binding inhibitor of coagulation: β2-glycoprotein I (apolipoprotein H). Proc Natl Acad Sci U S A. 1990;87:4120-4124.
3. Galli M, Comfurius P, Maassen C, et al. Anticardiolipin antibodies (ACA) directed not to cardiolipin but to a plasma protein cofactor. Lancet. 1990;335:1544-1547.
4. Wurm H. Beta2-glycoprotein I (apolipoprotein H) interactions with phospholipid vesicles. Int J Biochem. 1984;16:511-515.
5. Shi W, Chong BH, Chesterman CN. β2-glycoprotein I is a requirement for anticardiolipin antibodies binding to activated platelets: differences with lupus anticoagulant. Blood. 1993;81:1255-1262.
6. Del Papa N, Guidali L, Sala A, et al. Endothelial cells as target for antiphospholipid antibodies: human polyclonal and monoclonal anti-β2 glycoprotein I antibodies react in vitro with endothelial cells through adherent β2 glycoprotein I and induce endothelial activation. Arthritis Rheum. 1997;40:551-561.
7. Steinkasserer T, Estaller C, Weiss EH, Sim RB. Complete nucleotide and deduced amino acid sequence of human β2-glycoprotein I. Biochem J. 1991;277:387-391.
8. Hunt J, Krilis SA. The fifth domain of β2-glycoprotein I contains a phospholipid binding site (Cys281-Lys288) and a region recognized by anticardiolipin antibodies. J Immunol. 1994;152:653-659.
9. Matsuura E, Igarashi M, Igarashi Y, Ichikawa K, Koike T. Molecular studies on phospholipid binding sites and cryptic epitopes appearing on β2-glycoprotein I structures recognized by anticardiolipin antibodies. Lupus, 1995;4:S13-S17.
10. Sheng Y, Sali A, Herzog H, Lahnstein J, Krilis SA. Site-directed mutagenesis of recombinant human β2-glycoprotein I identifies a cluster of lysine residues that are critical for phospholipid binding and anti-cardiolipin antibody activity. J Immunol. 1996;157:3744-3751.
11. Bourma B, de Groot PG, van der Elsen JMH, et al. Adhesion mechanism of human β2-glycoprotein I to phospholipids based on its crystal structure. EMBO J. 1999;18:5166-5174.
12. Kaburaki J, Kuwana M, Yamamoto M, Kawai S, Matsuura E, Ikeda Y. Clinical significance of phospholipid-dependent anti-β2-glycoprotein I (β2-GPI) antibodies in systemic lupus erythematosus. Lupus. 1995;4:472-476.
13. Blank M, Faden D, Tincani A, et al. Immunization with anticardiolipin cofactor (bete-2-glycoprotein I) induces experimental antiphospholipid antibody syndrome in naive mice. J Autoimmun. 1994;7:441-455.
14. Garcia CO, Kanbour-Shakir A, Tang H, Molina JF, Espinoza LR, Gharavi AE. Induction of experimental antiphospholipid syndrome in PL/J mice following immunization with β2GPI. Am J Reprod Immunol. 1997;37:118-124.
15. Blank M, Cohen J, Toder V, Shoenfeld Y. Induction of anti-phospholipid syndrome in naive mice with mouse lupus monoclonal and human polyclonal anticardiolipin antibodies. Proc Natl Acad Sci U S A. 1991;88:3069-3073.
16. Branch DW, Dudley DJ, Mitchell MD, et al. Immunoglobulin G fractions from patients with antiphospholipid antibodies cause fetal death in BALB/c mice: a model for autoimmune fetal loss. Am J Obstet Gynecol. 1990;163:210-216.
17. Silver R, Pierangeli SS, Gharavi AE, et al. Induction of high levels of anticardiolipin antibodies in mice by immunization with β2-glycoprotein I dose not cause fetal death. Am J Obstet Gynecol. 1995;173:1410-1415.
18. Silver R, Smith L, Edwin SS, Oshiro BT, Scoff JR, Branch DW. Variable affects on murine pregnancy of immunoglobulin G fractions from women with antiphospholipid antibodies. Am J Obstet Gynecol, 1997;177:229-233.
19. George J, Blank M, Levy Y, et al. Differential effects of anti-beta 2 glycoprotein I antibodies on endothelial cells and on the manifestations of experimental antiphospholipid syndrome. Circulation, 1998;97:900-906.
20. Pierangeli SS, Colden-Stanfield M, Liu X, Barker JH, Anderson GL, Harris EN. Anti-phospholipid antibodies from antiphospholipid syndrome patients activate endothelial cells in vitro and in vivo. Circulation. 1999;99:1997-2002.
21. Hattori N, Kuwana M, Kaburaki J, Mimori T, Ikeda Y, Kawakami Y. T cells that are autoreactive to β2-glycoprotein I in patients with antiphospholipid syndrome and healthy individuals. Arthritis Rheum. 2000;43:65-75.
22. Wilson WA, Gharavi AE, T. Koike T, et al. International consensus statement on preliminary classification criteria for definite antiphospholipid syndrome. Arthritis Rheum. 1999;42:1309-1311.
23. Inoko H, Ota M. PCR-RFLP. In: Hui KM, Bidwell JL, eds. Handbook of HLA Typing Techniques. Boca Raton, FL: CRC Press; 1993:9-70.
24. Naruse T, Ando R, Nose Y, et al. HLA-DRB4 genotyping by PCR-RFLP: diversity in the associations between HLA-DRB4 and DRB1 alleles. Tissue Antigens, 1997;49:152-159.
25. Steinkasserer A, Dorner C, Wurzner R, Sim RB. Human beta2-glycoprotein I: molecular analysis of DNA and amino acid polymorphism. Hum Genet. 1993;91:401-402.
26. Matsuura E, Igarashi Y, Fujimoto M, et al. Heterogeneity of anticardiolipin antibodies defined by the anticardiolipin cofactor. J Immunol. 1992;148:3885-3890.
27. Matsuura E, Igarashi M, Igarashi Y, et al. Molecular definition of human β2-glycoprotein I (β2-GPI) by cDNA cloning and inter-species differences of β2-GPI in alternation of anticardiolipin binding. Int Immunol. 1991;3:1217-1221.
28. Kuwana M, Medsger TA Jr, Wright TM. Highly restricted TCR αβ usage by autoreactive human T cell clones specific for DNA topoisomerase I: recognition of an immunodominant epitope. J Immunol. 1997;158:485-491.
29. Inoko H, Bodmer JG, Heyes JM, Drover S, Trowsdale J, Marshall WH. Joint report on the transfectant/ monoclonal antibody component. In: Tsuji K, Aizawa M, Sasazuki K, eds. HLA 1991. Vol 2. New York, NY: Oxford University Press; 1992:919-930.
30. Kuwana M, Medsger TA Jr, Wright TM. Analysis of soluble and cell surface factors regulating anti-DNA topoisomerase I autoantibody production demonstrates synergy between Th1 and Th2 autoreactive cells. J Immunol. 2000;164:6138-6146.
31. Ito H, Matsushita S, Tokano Y, et al. Analysis of T cell responses to the β2-glycoprotein I-derived peptide library in patients with anti-β2-glycoprotein I antibody-associated autoimmunity. Hum Immunol. 2000;61:366-377.
32. Del Papa N, Sheng YH, Raschi E, et al. Human β2-glycoprotein I binds to endothelial cells through a cluster of lysine residues that are critical for anionic phospholipid binding and offers epitopes for anti-β2-glycoprotein I antibodies. J Immunol. 1998;160:5572-5578.
33. Pal'keeva M, Tishchenko V, Sidorova M, Bespalova Z, Ovchinnikov M. Binding of β2-gpl-dependent ACL with peptide sequence FCKNKEKKCS and peptide conjugates [abstract]. J Autoimmun. 2000;15:A36.
34. Wang M-X, Kandiah DA, Ichikawa K, et al. Epitope specificity of monoclonal anti-β2 glycoprotein I antibodies derived from patients with anti-phospholipid syndrome. J Immunol. 1995;155:1629-1636.
35. Iverson GM, Victoria EJ, Marquis DM. Anti-β2-glycoprotein I (β2-GPI) autoantibodies recognize an epitope on the first domain of β2-GPI. Proc Natl Acad Sci U S A. 1998;95:15542-15546.
36. George J, Gilburd B, Hojnik M, et al. Target recognition of β2-glycoprotein I (β2GPI)-dependent anticardiolipin antibodies: evidence for involvement of the fourth domain of β2GPI in antibody binding. J Immunol. 1998;160:3917-3923.
37. Gharavi AE, Pierangeli SS, Colden-Stanfield M, Liu X, Espinola RG, Harris EN. GDKV-induced antiphospholipid antibodies enhance thrombosis and activate endothelial cells in vivo and in vitro. J Immunol. 1999;163:2922-2927.
38. 2 glycoprotein I alone. Lupus. 1998;7:341-346.
39. Sebastiani GD, Galeazzi M, Morozzi G, Marcolongo R. The immunogenetics of the antiphospholipid syndrome, anticardiolipin antibodies, and lupus anticoagulant. Semin Arthritis Rheum, 1996;25:414-420.
40. Amett FC, Thiagarajan P, Ahn C, Reveille JD. Associations of anti-β2-glycoprotein I autoantibodies with HLA class II alleles in three ethnic groups. Arthritis Rheum. 1999;42:268-274.
41. Hashimoto H, Yamanaka K, Tokano Y, et al. HLA-DRB1 alleles and β2 glycoprotein I-dependent anticardiolipin antibodies in Japanese patients with systemic lupus erythematosus. Clin Exp Rheumatol. 1998;16:423-427.
42. Kobayashi H, Kokubo T, Abe Y, et al. Analysis of anchor residues in a naturally processed HLA-DR53 ligand. Immunogenetics. 1996;44:366-371.
43. Sanghera DK, Kristensen T, Hamman RF, Kamboh MI. Molecular basis of the apolipoprotein H (β2-glycoprotein I) protein polymorphism, Hum Genet. 1997;100:57-62.
44. Visvanathan S, McNeil HP. Cellular immunity to β2-glycoprotein I in patients with the antiphospholipid syndrome. J Immunol. 1999;162:6919-6925.
45. Visvanathan S, Geczy CL, Harmer JA, McNeil HP, Monocyte tissue factor induction by activation of β2- glycoprotein-I-specific T lymphocytes is associated with thrombosis and fetal loss in patients with antiphospholipid antibodies. J Immunol. 2000;165:2258-2262.
46. Lehmann PV, Sercarz EE, Forsthuber T, Dayan CM, Gammon G. Determinant spreading and the dynamics of the autoimmune T-cell repertoire. Immunol Today. 1993;14:203-208.
47. Lanzavecchia A. How can cryptic epitopes trigger autoimmunity? J Exp Med 1995;181:1945-1948.
48. Dong X, Hamilton KJ, Satoh M, Wang J, Reeves WH. Initiation of autoimmunity to the p53 tumor suppressor protein by complexes of p53 and SV40 large T antigen. J Exp Med 1994;179:1243-1252.
49. Subang R, Levine JS, Janoff AS, et al. Phospholipidbound β2-glycoprotein I induces the production of anti-phospholipid antibodies. J Autoimmun. 2000;15:21-32.
50. Levine JS, Subang R, Koh JS, Rauch J. Induction of anti-phospholipid autoantibodies by β2-glycoprotein I bound to apoptotic thymocytes. J Autoimmun. 1998;11:413-424.
51. Sloan-Lancastar J, Evavold BD, Allen PM. Induction of T-cell anergy by altered T-cell-receptor ligand on live antigen-presenting cells. Nature. 1993;363:156-159.
52. + T-cell subset inhibits antigen-specific T-cell responses and prevents colitis. Nature. 1997;389:737-742.
53. Yoshizaki K, Nishimoto N, Mihara M, Kishimoto T. Therapy of rheumatoid arthritis by blocking IL-6 signal transduction with a humanized anti-IL-6 receptor antibody. Springer Semin Immunopathol. 1998;20:247-59.
54. Davis JC, Totoritis MC, Rosenberg J, SklenarTA, Wofsy D. Phase I clinical trial of a monoclonal antibody against CD40-ligand (IDEC-131) in patients with systemic lupus erythematosus. J Rheumatol. 2001;28:95-101.